My doctor understands Alpha-1

Resources for HCPs

CSL Behring provides a broad range of resources and materials to assist physicians in the treatment of Alpha-1:

How to enroll your patients in the Zemaira Sample program

Download the Zemaira Sample Request form and your CareZ team will do the rest.

Please note that Zemaira samples can be requested only on a per-patient basis.

Start today. Your Zemaira CareZ® team will:

  • Contact you within 24 hours.
  • Complete patient benefit investigation and coordinate access to care.
  • Connect your patient to valuable educational resources, financial assistance, and peer support.

For more information about the Zemaira Sample program, please call 1-866-ZEMAIRA (1-866-936-2472).

Back to top

Continuing Education

The Alpha-1 Foundation offers a CME program to help educate healthcare professionals on the standards for the diagnosis and management of Alpha-1.

Back to top

Web Resources

  • The Alpha-1 Foundation
    Provides leadership and resources to increase research, improve health, achieve worldwide detection, and find a cure for Alpha-1. This site contains an excellent explanation of Alpha-1, provides health tips, and offers a free Alpha-1 testing kit
  • The American Thoracic Society
    Focuses on respiratory and critical care medicine, with a long-range goal of decreasing morbidity and mortality from respiratory disorders and life-threatening acute illnesses. The Society helps to set the standards for prevention, treatment, and control of these serious diseases
  • Accredo
    Distributes Zemaira and has the country's most extensive network of pharmacies dedicated to the treatment of Alpha-1
  • Coram
    A leader in home infusion services and specialty pharmacy distribution, proudly distributing Zemaira through more than 75 locations nationwide. In addition to caring for diagnosed Alpha-1 patients and offering an extensive patient advocacy program, Coram takes an active role in promoting testing for this disease

Back to top

Clinical Reprints

Select any of the following journal articles on alpha1 antitrypsin deficiency or Zemaira that are of interest to you. CSL Behring will send your selection(s), as well as future updates on alpha1 antitrypsin deficiency and Zemaira, via e-mail.a





 

Please complete the fields below to receive your selected readings

(*indicates a required field)

  • Type in the verification word in the box below and click "Submit."

    Verification Word

Prior to submitting your information, please review our Privacy Policy.

a This list of resources is provided as a service by CSL Behring LLC. Publication of these resources by CSL Behring does not necessarily constitute our approval or endorsement of viewpoints, inferences, or conclusions stated in or implied by the authors of these materials. Listed resources were accurate at the time of publication. CSL Behring LLC is not responsible for changes in resource information.

Back to top

CSL Behring Medical Affairs Department

Get answers to all of your questions regarding Alpha-1 by contacting CSL Behring Medical Affairs:

Phone: 800-504-5434
Fax: 610-878-4007
E-mail: Contact Us

You may also send correspondence by mail to the following address:

Medical Information
North American Headquarters
CSL Behring
PO Box 61501
1020 First Avenue
King of Prussia, PA 19406 USA

Back to top

CareZ®

CSL Behring makes managing the treatment of Alpha-1 as easy as possible for you and your staff through our comprehensive suite of patient support programs, CareZ.

  • Alpha-1 is a complicated disease with complicated patient support needs
  • CareZ provides resources and services to help manage the treatment of Alpha-1, while delivering the educational, physical, emotional, and financial support your patients need
Learn about all that the CareZ community has to offer you, your staff, and your patients.


Back to top

Get Your Alpha-1 Patients Started on Zemaira Today

  • 3 easy enrollment steps
  • 1 point of contact
  • Lifelong patient support from CareZ®
Complete Referral Form

The Benefits of Zemaira

See the clinical data supporting the benefits of Zemaira

Read More

Important Safety Information

Alpha1-Proteinase Inhibitor (Human), Zemaira® is indicated for chronic augmentation and maintenance therapy for adults with alpha1-proteinase inhibitor (A1-PI) deficiency and emphysema. No clinical data are available demonstrating the effect of augmentation therapy with Zemaira or any A1-PI product on the progression of emphysema in A1-PI deficiency.

Zemaira is not indicated for lung disease patients in whom severe A1-PI deficiency has not been established.

Zemaira is contraindicated in patients with a history of severe systemic reactions to the product or to A1-PI protein, including anaphylaxis. Due to the risk of severe hypersensitivity, Zemaira is also contraindicated in immunoglobulin A-deficient patients with antibodies against IgA.

Use caution in administering Zemaira to patients who have experienced anaphylaxis or severe systemic reactions to another A1-PI product. Patients with selective or severe IgA deficiency can develop antibodies to IgA and are at greater risk of such reactions. If anaphylactic or severe anaphylactoid reactions occur during infusion, discontinue immediately.

In clinical studies, the following adverse reactions were reported in at least 5% of subjects receiving Zemaira: headache, sinusitis, upper respiratory infection, bronchitis, asthenia, increased cough, fever, injection-site hemorrhage, rhinitis, sore throat, and vasodilation.

Zemaira is derived from human plasma. The risk of transmission of infectious agents, including viruses and, theoretically, the Creutzfeldt-Jakob disease (CJD) agent, cannot be completely eliminated.

Please see full prescribing information for Zemaira.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.